Kimberly Rosko

Discovery of <i>N</i>-[(1<i>S</i>,2<i>S</i>)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a Novel, Acyclic Cannabinoid-1 Receptor Inverse Agonist for the Treatment of Obesity

Linus S. Lin, Thomas J. Lanza, James P. Jewell et al. · Journal of Medicinal Chemistry · 2006 · 122 citations · Full text

Cannabis Use, Molecular Pharmacology, Medicinal Chemistry +15

Dose-dependent quantitative effects of acute fructose administration on hepatic de novo lipogenesis in healthy humans

Carine Beysen, Marcella Ruddy, Aubrey Stoch et al. · American Journal of Physiology-Endocrinology and Metabolism · 2018 · 44 citations · Full text

Substituted acyclic sulfonamides as human cannabinoid-1 receptor inverse agonists

Helen E. Armstrong, Amy Galka, Linus S. Lin et al. · Bioorganic & Medicinal Chemistry Letters · 2007 · 15 citations · Full text

Cannabis Use, Molecular Pharmacology, Biochemistry +8

Pharmacokinetics, Safety, and Tolerability of Phentermine in Healthy Participants Receiving Taranabant, a Novel Cannabinoid‐1 Receptor (CB1R) Inverse Agonist

Carol Addy, Patricia Jumes, Kimberly Rosko et al. · The Journal of Clinical Pharmacology · 2009 · 13 citations

Inverse Agonist, Pharmacotherapy, Cannabinoid Pharmacology +16

Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents

Lauren P. Shearman, D. Sloan Stribling, Ramon E. Camacho et al. · European Journal of Pharmacology · 2007 · 12 citations

Cannabis Use, Molecular Pharmacology, Functional Selectivity +8